A new methodology to predict the oncotype scores based on clinico-pathological data with similar tumor profiles.
Fiche publication
Date publication
novembre 2023
Journal
Breast cancer research and treatment
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEVALLAND Christine
Tous les auteurs :
Al Masry Z, Pic R, Dombry C, Devalland C
Lien Pubmed
Résumé
The Oncotype DX (ODX) test is a commercially available molecular test for breast cancer assay that provides prognostic and predictive breast cancer recurrence information for hormone positive, HER2-negative patients. The aim of this study is to propose a novel methodology to assist physicians in their decision-making.
Mots clés
Breast Cancer, Clinico-pathological data, Distributional Random Forest, Machine Learning, Oncotype DX
Référence
Breast Cancer Res Treat. 2023 11 6;: